Financial comparisons MannKind Corporation
Equities
MNKD
US56400P7069
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.580 USD | -0.53% |
|
-7.15% | -1.59% |
| 01-08 | MannKind provides business updates and 2026 growth drivers | RE |
| 12-23 | MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 286M | 9.66% | 25.42% | - | - | - | |
| 2.22B | 36.99% | -0.96% | 2.26% | 2.02% | 818.71x | |
| 5.38B | 24.08% | 29.51% | 16.78% | 12.27% | -0.97x | |
| 364M | -251.24% | -241.47% | -1,601.19% | -54.47% | 0.16x | |
| 2.85B | -24.18% | -47.77% | -3.3% | -2.88% | 9.36x | |
| 2.99B | 36.44% | 32.53% | 22.97% | 19.34% | -2.97x | |
| 2.56B | 17.97% | 25.37% | 11.65% | 8.43% | -0.66x | |
| 291M | -24.22% | -26.28% | -8.94% | -4.69% | -2.82x | |
| 265M | -13.8% | -7.18% | -9.46% | -9.11% | 18.95x | |
| 2.17B | 24.04% | 27.88% | 23.13% | 17.7% | -1.75x | |
| 180M | -258.64% | -276.39% | -80.35% | - | 1.63x | |
| 829M | -0.2% | 11.86% | -0.5% | - | -6.61x | |
| 18.47M | -3,191.11% | -2,902.72% | - | -52.97% | 0.77x | |
| 235M | -85.53% | -78.53% | -54.06% | -26.62% | -1.54x | |
| 22.61M | -165.69% | -177.21% | -45.83% | -28.23% | 1.93x | |
| 36.13M | -595.93% | -752.96% | -42.88% | - | 1.96x | |
| Average | 1.29B | -278.83% | -272.43% | -126.41% | -9.93% | 55.74x | |
| Weighted average by Cap. | 2.08B | -134.98% | -137.32% | -196.35% | -5.79% | 142.38x |
- Stock Market
- Equities
- MNKD Stock
- Sector MannKind Corporation
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition